Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Suzhou Highfine Biotech CoSZSE:301393 -3.26%93 EBITDA Margin % is 21.97% as of Mar. 2026, which is 31% below its 10-year median of 31.91. GuruFocus rates SZSE:301393 with a GF Score™ of 93/100 and a GF Value™ of ¥71.11 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 960 Drug Manufacturers companies, Suzhou Highfine Biotech Co ranks better than 67.81% on this metric.
Suzhou Highfine Biotech Co (SZSE:301393) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Suzhou Highfine Biotech Co EBITDA Margin % Related Terms
Suzhou Highfine Biotech Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Suzhou Highfine Biotech Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Suzhou Highfine Biotech Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Suzhou Highfine Biotech Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Suzhou Highfine Biotech Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Suzhou Highfine Biotech Co (SZSE:301393) has a EBITDA Margin % of 21.97% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Suzhou Highfine Biotech Co and its competitors. This is 31% below median its historical median of 31.91. Over the past decade, Suzhou Highfine Biotech Co's EBITDA Margin % has ranged from 19.93 to 39.89. According to the industry distribution chart, Suzhou Highfine Biotech Co ranks #309 out of 960 companies in the Drug Manufacturers industry, placing it in the top 32.2%.
Is Suzhou Highfine Biotech Co's EBITDA Margin % too high?
Suzhou Highfine Biotech Co's current EBITDA Margin % of 21.97% is 31% below median its 10-year median of 31.91. Over the past 10 years, this metric has ranged from a low of 19.93 to a high of 39.89. The Drug Manufacturers industry median EBITDA Margin % is 12.45. Suzhou Highfine Biotech Co's value of 21.97% is 76.5% above this industry median. Based on the distribution chart, Suzhou Highfine Biotech Co ranks #309 out of 960 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Suzhou Highfine Biotech Co has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Suzhou Highfine Biotech Co's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Suzhou Highfine Biotech Co ranks #309 out of 960 companies for EBITDA Margin %. This puts Suzhou Highfine Biotech Co in the upper half of its industry. The industry median EBITDA Margin % is 12.45. Suzhou Highfine Biotech Co's value of 21.97% is 76.5% above this benchmark. Historically, Suzhou Highfine Biotech Co's own EBITDA Margin % has ranged from 19.93 to 39.89 over the past decade. While the company's 10-year median is 31.91 vs. the industry median of 12.45, Suzhou Highfine Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.45, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Suzhou Highfine Biotech Co's current EBITDA Margin % of 21.97% is 76.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Suzhou Highfine Biotech Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Suzhou Highfine Biotech Co's current EBITDA Margin % is 21.97%, which is 31% below median its own 10-year median of 31.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suzhou Highfine Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Suzhou Highfine Biotech Co (SZSE:301393) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥71.11, compared to a current price of ¥56.75 — trading 20.2% below its estimated fair value. The current EBITDA Margin % is 21.97%, which is 31% below median its 10-year median of 31.91 and 76.5% above the Drug Manufacturers industry median of 12.45. Suzhou Highfine Biotech Co's overall GF Score™ is 93/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Suzhou Highfine Biotech Co (SZSE:301393), the current EBITDA Margin % is 21.97% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Suzhou Highfine Biotech Co (SZSE:301393) Overvalued in 2026?
Based on GuruFocus' analysis, Suzhou Highfine Biotech Co stock appears to be undervalued.
The current stock price of ¥56.75 is trading 20.2% below its estimated GF Value™ of ¥71.11.
GuruFocus considers Suzhou Highfine Biotech Co to be Modestly Undervalued.
Key valuation signals for SZSE:301393:
EBITDA Margin %: 21.97% (31% below median its 10-year median of 31.91)
GF Value™: ¥71.11 vs. price of ¥56.75 (20.2% below fair value)
Industry Position: 76.5% above the Drug Manufacturers median (#309 of 960)
No single metric tells the full story. See the SZSE:301393 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Suzhou Highfine Biotech Co Ltd is a high-tech enterprise that provides characteristic raw materials for global pharmaceutical research and development and raw material drug production companies. The products are mainly used in the fields of peptide, nucleotide and pharmaceutical synthesis. The product range covers peptide synthesis reagents for characteristic amide bond formation, molecular building blocks, protein reagents, liposome and lipid nanoparticle pharmaceutical reagents, ionic liquids , PROTAC reagents and nucleotide reagents and other types.
93GF Score
Get the complete analysis for SZSE:301393
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:301393 has been successfully added to your 
